Track MannKind Corporation — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

MannKind Corporation MNKD Open MannKind Corporation in new tab

2.50 USD
P/E
114.00
EPS
0.02
P/B
-13.73
Beta
0.93
Target Price
7.50 USD
MannKind Corporation logo

MannKind Corporation

🧾 Earnings Recap – Q3 2025

MannKind Corporation reported a record revenue of $82 million in Q3 2025, driven by strong product performance and the recent acquisition of scPharmaceuticals, positioning the company for significant growth ahead.

  • Q3 2025 revenue reached $82 million, marking a record for the company, with Tyvaso DPI contributing $59 million in royalties and manufacturing revenue.
  • The supplemental BLA for Afrezza was accepted for review, with a PDUFA date set for Q2 2026, highlighting potential pediatric market entry.
  • FUROSCIX revenue grew by 95% year-to-date compared to 2024, with significant adoption, including over 27,000 doses dispensed in Q3, anticipated to reflect in Q4 results post-acquisition.
  • The acquisition of scPharmaceuticals enhances MannKind's commercial scale and accelerates growth into cardiorenal medicine, targeting a substantial market opportunity in heart failure and chronic kidney disease.
  • Afrezza prescription growth continued, with a 31% increase in new prescriptions year-over-year, despite a shift in focus towards type 1 diabetes.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 6, 2026
P/E114.00
EPS0.02
Book Value-0.17
Price to Book-13.73
% Insiders1.767%
Growth
Revenue Growth0.46%
Earnings Growth-0.35%
Estimates
Forward P/E10.02
Forward EPS0.23
Target Mean Price7.50

DCF Valuation

Tweak assumptions to recompute fair value for MannKind Corporation (MNKD)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

MannKind Corporation Logo MannKind Corporation Analysis (MNKD)

United States Health Care Official Website Stock

Is MannKind Corporation a good investment? MannKind Corporation (MNKD) is currently trading at 2.50 USD. Market analysts have a consensus price target of 7.50 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 114.00. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: MannKind Corporation is expected to release its next earnings report on May 6, 2026. The market consensus estimate for Forward EPS is 0.23.

Investor FAQ

Does MannKind Corporation pay a dividend?

No, it does not currently pay a dividend.

What asset class is MannKind Corporation?

MannKind Corporation is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be May 6, 2026. The company currently has a trailing EPS of 0.02.

Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Exchange Ticker
NMS (United States) MNKD
FRA (Germany) NNFN.F

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
March 3, 2017 0.200000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion